Interactive educational diabetes/insulin tutorial at www.2aida.info.

abstract：BACKGROUND:This exploratory study examined the pharmacokinetics and pharmacodynamics of a Bentley Pharmaceuticals, Inc. (North Hampton, NH) proprietary insulin formulation utilizing CPE-215 technology designed for intranasal administration. METHODS:Eight fasting healthy volunteers (four men, four women; body mass inde...

journal_title：Diabetes technology & therapeutics

authors： Leary AC,Stote RM,Breedt HJ,O'Brien J,Buckley B

更新日期：2005-02-01 00:00:00

abstract：:The transplantation of microencapsulated islets may allow reversal of hyperglycemia in the absence of immunosuppression. Poly-L-lysine (PLL) on capsules may potentiate the fibrotic reaction against implanted capsules. The aims of this study were to investigate how the biocompatibility of such capsules affects their fu...

journal_title：Diabetes technology & therapeutics

authors： King A,Lau J,Nordin A,Sandler S,Andersson A

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Lipohypertrophy (LH) is a complication of insulin therapy. We assessed LH prevalence, risk factors, insulin usage, and clinical and health economic effects in China. METHODS:In four cities, 401 adult patients injecting insulin ≥1 year were surveyed for diabetes/insulin injection history and practices, pen n...

journal_title：Diabetes technology & therapeutics

authors： Ji L,Sun Z,Li Q,Qin G,Wei Z,Liu J,Chandran AB,Hirsch LJ

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Applying real-time learning into an artificial pancreas system could effectively track the unpredictable behavior of glucose-insulin dynamics and adjust insulin treatment accordingly. We describe a novel learning algorithm and its performance when integrated into the MD-Logic Artificial Pancreas (MDLAP) syst...

journal_title：Diabetes technology & therapeutics

authors： Miller S,Nimri R,Atlas E,Grunberg EA,Phillip M

更新日期：2011-10-01 00:00:00

abstract：: Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an invest...

journal_title：Diabetes technology & therapeutics

authors： Sherr JL,Buckingham BA,Forlenza GP,Galderisi A,Ekhlaspour L,Wadwa RP,Carria L,Hsu L,Berget C,Peyser TA,Lee JB,O'Connor J,Dumais B,Huyett LM,Layne JE,Ly TT

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:A brief history of the field of human factors research is covered, along with how this discipline is leveraged within medical device companies, to eliminate design flaws in products, in order to make them safe and effective for human use. The way in which human factors research was used to develop the t:slim...

journal_title：Diabetes technology & therapeutics

authors： Schaeffer NE

更新日期：2013-10-01 00:00:00

abstract：:It is widely accepted that noninvasive glucose monitoring (NIGM) has the potential to revolutionize diabetes therapy. However, current approaches to NIGM studied to date have not yet demonstrated a level of acceptable functionality to allow real-time use, beyond restricted fields of application. A number of reviews ha...

journal_title：Diabetes technology & therapeutics

authors： Caduff A,Talary MS,Zakharov P

更新日期：2010-01-01 00:00:00

abstract：:Hyperspectral imaging (HSI) has been useful in monitoring several medical conditions, which to date have generally involved local changes in skin oxygenation of isolated regions of interest such as skin flaps or small burns. Here, by contrast, we present a study in which HSI was used to assess the local cutaneous mani...

journal_title：Diabetes technology & therapeutics

authors： Gillies R,Freeman JE,Cancio LC,Brand D,Hopmeier M,Mansfield JR

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:The objective of this investigation was to evaluate the test-retest repeatability of insulin sensitivity and secretion indices derived from liquid meal tolerance tests (MTTs) in subjects with normal fasting glucose (NFG) (n = 20), impaired fasting glucose (IFG) (n = 20), or type 2 diabetes mellitus (n = 38)....

journal_title：Diabetes technology & therapeutics

authors： Maki KC,Rains TM,Dicklin MR,Bell M

更新日期：2010-11-01 00:00:00

abstract：:Since the late 1970s, self-monitoring of blood glucose has been the standard for assessing daily glycemic control. The first continuous glucose monitor became available in 1999. Numerous clinical trials have documented the benefits of continuous glucose monitoring (CGM) in patients with type 1 diabetes mellitus (DM). ...

journal_title：Diabetes technology & therapeutics

authors： Meade LT

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may...

journal_title：Diabetes technology & therapeutics

authors： Clements M,Matuleviciene V,Attvall S,Ekelund M,Pivodic A,Dahlqvist S,Fahlén M,Haraldsson B,Lind M

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Patients undergoing intensive insulin therapy may have blood glucose (BG) samples drawn from arterial, capillary, or venous sources. This study compared capillary and venous BG across a range of glucose concentrations and under conditions of rapid change in BG. METHODS:Following a 10-h fast, 40 adult patien...

journal_title：Diabetes technology & therapeutics

authors： Kempe K,Price D,Ellison J,Marhoul J,Morrow L,Win K,Kuschma K,Hompesch M

更新日期：2009-10-01 00:00:00

abstract：:Diabetic nephropathy is one of the major causes of end-stage renal disease and is often associated with other macrovascular complications such as ischemic heart disease and peripheral vascular disease. Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (AIIR) have both been shown to ...

journal_title：Diabetes technology & therapeutics

authors： Boner G,Cao Z,Cooper ME

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), wa...

journal_title：Diabetes technology & therapeutics

authors： Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

更新日期：2007-04-01 00:00:00

abstract：:There is a clear role for inflammation in the development of type 2 diabetes and its associated co-morbidities. Circulating inflammatory markers such as C-reactive protein, sialic acid, and interleukin- 6 are all significant independent predictors of disease. A number of nutritional components are hypothesized to modu...

journal_title：Diabetes technology & therapeutics

authors： Browning LM,Jebb SA

更新日期：2006-02-01 00:00:00

abstract：:It is becoming increasingly acknowledged that people with Type 2 Diabetes represent what can be termed "an enriched population": a group that has the greatest risk of morbidity and mortality from cardiovascular diseases such as myocardial infarcts and strokes. Due to the tremendous toll, both human and financial, that...

journal_title：Diabetes technology & therapeutics

authors： Marcus AO

更新日期：2000-07-01 00:00:00

abstract：BACKGROUND:Narcolepsy is a severe sleep disorder that in most patients is characterized by the deficiency of central orexin. Clinically, narcolepsy is associated with obesity. Currently, there is a literature controversy about the potential alteration of leptin levels in narcoleptic patients. Theoretically, diminished ...

journal_title：Diabetes technology & therapeutics

authors： Dahmen N,Engel A,Helfrich J,Manderscheid N,Löbig M,Forst T,Pfützner A,Tonn P

更新日期：2007-08-01 00:00:00

abstract：BACKGROUND:Improved insulin infusion set survival and faster insulin action are important issues for pump users and for the development of an artificial pancreas. The current recommendation is to change infusion sets every 3 days. Our objectives were to determine the effect of lipohypertrophy (LH) on infusion set survi...

journal_title：Diabetes technology & therapeutics

authors： Karlin AW,Ly TT,Pyle L,Forlenza GP,Messer L,Wadwa RP,DeSalvo DJ,Payne SL,Hanes S,Clinton P,Maahs DM,Buckingham B

更新日期：2016-07-01 00:00:00

abstract：:Innovo (Novo Nordisk A/S, Hillerød, Denmark) is a new insulin injection system that offers built-in memory and a large, clear display to provide patients with more control during insulin injections. The aim of this trial was to compare the efficacy and safety of Innovo and NovoPen 3 (Novo Nordisk A/S) in patients expe...

journal_title：Diabetes technology & therapeutics

authors： Valk NK,Cerny G,Sieber J,Lytzen L,Berg B

更新日期：2004-02-01 00:00:00

abstract：: Objective: To assess the safety and efficacy of a simplified initialization for the Tandem t:slim X2 Control-IQ hybrid closed-loop system, using parameters based on total daily insulin ("MyTDI") in adolescents with type 1 diabetes under usual activity and during periods of...

journal_title：Diabetes technology & therapeutics

authors： Schoelwer MJ,Robic JL,Gautier T,Fabris C,Carr K,Clancy-Oliveri M,Brown SA,Anderson SM,DeBoer MD,Cherñavvsky DR,Breton MD

更新日期：2020-08-01 00:00:00

abstract：:Rates of diabetes are increasing worldwide and there is not a sufficient clinical workforce to care for these patients. Diabetes-related apps are a feasible way to provide diabetes education to large numbers of people with diabetes but attrition rates are high. Apps enhanced by virtual coaching may be a way to circumn...

journal_title：Diabetes technology & therapeutics

authors： Ramchandani N

更新日期：2019-06-01 00:00:00

abstract：: Background: The use of real-time continuous glucose monitoring (rtCGM) systems has proved to positively impact the management of type 1 diabetes with the potential to lower HbA1c, reduce frequency and time spent in hypoglycemia, and lower glycemic variability. Nevertheless...

journal_title：Diabetes technology & therapeutics

authors： Deiss D,Szadkowska A,Gordon D,Mallipedhi A,Schütz-Fuhrmann I,Aguilera E,Ringsell C,De Block C,Irace C

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

journal_title：Diabetes technology & therapeutics

authors： Schwartz S,Vlajnic A

更新日期：2008-10-01 00:00:00

abstract：:The World Wide Web has become remarkably quickly an alternative source of information for patients and their relatives, as well as students and health-care professionals. A whole plethora of websites and Internet-based applications related to diabetes have appeared in recent years. In this column, selected issues surr...

journal_title：Diabetes technology & therapeutics

authors： Lehmann ED

更新日期：2005-02-01 00:00:00

abstract：BACKGROUND:Insulin initiation and optimization is a challenge for patients with type 2 diabetes. Our objective was to determine whether safety and efficacy of AIR inhaled insulin (Eli Lilly and Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., Cambridge, MA) using a simplified regimen was noninfe...

journal_title：Diabetes technology & therapeutics

authors： Mathieu C,Cuddihy R,Arakaki RF,Belin RM,Planquois JM,Lyons JN,Heilmann CR

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:As healthy diet and physical activity can improve glucometabolic control in patients with type 2 diabetes, lifestyle changes should be the basis for each therapy. The only tool to visualize immediate effects of food pattern and exercise on blood glucose levels is self-monitoring of blood glucose (SMBG). Ther...

journal_title：Diabetes technology & therapeutics

authors： Kempf K,Kruse J,Martin S

更新日期：2010-07-01 00:00:00

abstract：BACKGROUND:Programmable and fixed auditory and/or vibratory threshold alerts are essential features of real-time continuous glucose monitoring (rtCGM) systems that provide users time to intervene before the onset of clinical hypoglycemia or hyperglycemia. A sixth-generation rtCGM system from Dexcom, Inc. (G6) includes ...

journal_title：Diabetes technology & therapeutics

authors： Puhr S,Derdzinski M,Welsh JB,Parker AS,Walker T,Price DA

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12. METHODS:On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and und...

journal_title：Diabetes technology & therapeutics

authors： Bailey TS,Zisser HC,Garg SK

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Obstructive sleep apnea (OSA), a highly prevalent condition, is independently associated with increased risks of developing type 2 diabetes mellitus (T2D) and metabolic syndrome. It is unclear, however, if the severity of OSA has any impact on glycemic control among patients with T2D. We therefore aimed to d...

journal_title：Diabetes technology & therapeutics

authors： Pillai A,Warren G,Gunathilake W,Idris I

更新日期：2011-09-01 00:00:00